Share

    


In This Section

Home / Advocate / Cancer Moonshot

Cancer Moonshot

On February 2, 2022, President Biden announced plans to revamp the federal Cancer Moonshot program he spearheaded in 2016, with a goal of reducing the cancer death rate by at least 50% over the next 25 years and improving the experience of people and their families living with and surviving cancer by increasing cancer screenings, increasing access to clinical trials, and investing in new treatments, among other initiatives.

To help in this effort, ACCC made available to the White House resources and tools from its member programs, with a specific focus on cancer prevention for underserved and marginalized patient populations. Read More.

On Wednesday, May 11, 2022, leaders from the patient and caregiver community, foundations, non-profits, companies, healthcare providers, and others came together at the White House and virtually at the “Cancer Moonshot: Goals Forum.” In September, ACCC was again invited to attend and participate in ongoing Moonshot activities, this time in Boston at the Kennedy Library. Lekan Ajayi, PharmD, MBA, ACCC's President-Elect attended the session in Boston.

The President and First Lady announced a call to action on cancer screening to jumpstart progress on the nearly 10 million screenings in the United States that were missed as a result of the pandemic.

ACCC was identified by the White House as one of the five private sector actions in response to the goal of Bringing Cancer Screening to More Communities for its efforts to create the “Rural Appalachian Lung Cancer Screening Initiative." Read more on whitehouse.gov.

As Cancer Moonshot reignites, ACCC will continue to support the White House and leverage the expertise and resources of its member programs to achieve equitable quality care for all patients with cancer and their families. Stay tuned for ways you can get involved!

FROM THE ACCCBUZZ BLOG

Podcast

  • [MINI-PODCAST] AMCCBS Live: Cancer Moonshot
    Mar 3, 2022

    Dr. Jennie R. Crews, ACCC 2016-17 President, discusses ACCC's involvement in the White House's Cancer Moonshot initiative--from its launch in 2016 to the new energy generated by President Biden's revamp of the program in February 2022. Then hear how ACCC's legislative priorities into the Cancer Moonshot's commitment to increase cancer survivorship and reduce barriers to equitable cancer care.

Special Blog Series

To obtain an on-the-ground perspective of how cancer programs’ screening and outreach education efforts are recovering from pandemic pressures, the ACCCBuzz blog spoke to four cancer programs in January 2022 for “The Long Road to Recovery: A Snapshot of Cancer Screening in the U.S.”

  • Mary Bird Perkins Cancer Center, Louisiana
  • St. Elizabeth Healthcare, Kentucky
  • ChristianaCare, Delaware
  • Munson Healthcare, Michigan

Read what these ACCC member programs across the country are doing today to improve equitable screening and outreach.

From the White House

From Oncology Issues

  •  Editor: ACCC and the Biden Cancer Initiative
    Jennie R. Crews, MD, MMM, FACP
    On Sept. 21, the Biden Cancer Initiative Summit convened in Washington, D.C., and was joined by 450 community summits across the country to bring together those who work to improve the cancer experience for patients and caregivers.
  •  ACCC President’s Message: Advocacy Now!
    Jennie R. Crews, MD, MMM, FACP
    As we head into a New Year with a new Administration in the White House, we can be certain that now more than ever the oncology community must continue to be the strong, clear voice for access to quality cancer care delivery in all settings of care.
  •  • Bringing the Moonshot Down to Earth: What the taskforce means for ACCC members
    Leah Ralph
    On January 12, 2016, President Obama used his State of the Union address to announce that Vice President Biden would be leading a national moonshot to end cancer as we know it.
  •  Putting the Future of Cancer in Focus: The Moonshot Summit
    Jennie R. Crews, MD, MMM, FACP
    The Moonshot Summit brought together a diverse group of stakeholders, including cancer patients, advocacy groups, researchers, providers, and members of industry, including technology, IT, and drug development.